Actos

Actos (pioglitazone) is a medication used to regulate insulin in patients diagnosed with type II diabetes.

Despite the concerns associated with the linkage between Actos and bladder cancer, the European Commission advocates that Actos is still a

Actos (pioglitazone) was first introduced in July of 1999 and was designed to aid the body’s sensitivity to insulin in patients that have been diagnosed with type II diabetes.

A class action lawsuit has been filed on behalf of consumers who have developed bladder cancer after taking the popular diabetes medication, Actos, manufactured by Japan’s largest drug maker Takeda

Hundreds of thousands of patients who claim there is a linkage between Actos^® and bladder cancer are currently filing lawsuits

Actos® was first introduced in July of 1999. Prescribed to treat type II diabetes, the drug became popular for its ability to effectively regulate insulin.

In September 2010 at the Madison County, Illinois Circuit County Court, Robert and Jewell Bettorf filed an actos bladder cancer lawsuit ag

The U.S.

The link between Actos medication and bladder cancer has caused sales for Takeda Pharmaceuticals to drop in recent months.

Actos® was released in July of 1999 and was intended for the purpose of increasing the body’s sensitivity to insulin in patients diagnosed with type II diabetes.